The European Medicines Agency (EMA) recommended a Depo-Provera meningioma increased risk warning in September 2024. One wonders why the FDA has not followed this EMA regulatory action. Therefore, the Depo-Provera drug label in the US still does not include a warning about the meningioma increased … More
Main Navigation Menu
➤ About the Law Offices of Thomas J. Lamb
PRACTICE AREAS
➤ Asbestos and Mesothelioma Claims
➤ Benzene Cancer and Disease Claims
➤ Pharmaceutical Drug Injury Lawsuits
➤ Breast Implants Lymphoma Cancer Lawsuits
➤ Free Case Evaluation by Lawyer Tom Lamb
INFORMATION
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Our "Recent Articles" Archives
To save time, you can use our Quick Contact Form to tell us about your possible case.
Recent Articles
Treatment of Pleural Mesothelioma: ASCO Guideline Update
Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018 considerable progress has been made which has changed not only the management but even the name of this disease. This … More
Why Are There Depo-Provera Brain Tumor Warnings In Europe But Not US?
Depo-Provera brain tumor lawsuits for women who have been diagnosed with intracranial meningioma, a specific type of brain tumor, are being filed against the responsible pharmaceutical companies. A primary focus of these legal cases will be why the Depo-Provera drug label in the US does not include … More
The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma
Abstract: Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, … More
Andexxa Drug Injury Lawsuits for Blood Clots, PE, DVT
Andexxa (andexanet) is a treatment currently used when the reversal of anticoagulation is needed for life-threatening or uncontrolled bleeding in patients who are using Eliquis (apixaban) or Xarelto (rivaroxaban) at the time. Andexxa drug injury lawsuits for patients who developed blood clots … More
Ozempic Vision Loss Due to Increased Risk of NAION
Here is the most recent development concerning Ozempic vision loss and blindness: The European Union’s drug regulator said it would assess two new Danish studies that link Novo Nordisk’s popular diabetes drug Ozempic to a rare eye disease. The studies published earlier this week had found … More